Evidence map›Paper›PMID 42323288›Full record

ArticleCell death & disease2026

Restoring O-glycosylation and expression of MUC2 limits progression of colorectal cancer.

Yian Yang, Yuesong Yin, Wei Xu, Yan Kang, Jiawei Chen, Yanfeng Zou, Xuan Wang, Zhigang Xiao, Peiguo Cao, Zheng Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. UnravelingAnalytical chemistry · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yian YangDepartment of Oncology, the Third Xiangya Hospital, Central South University, Changsha, China.
Yuesong YinDepartment of Orthopedics, the Third Xiangya Hospital, Central South University, Changsha, China.
Wei XuNHC Key Laboratory of Carcinogenesis, Cancer Research Institute, School of Basic Medical Science, Central South University, Changsha, China.
Yan KangNHC Key Laboratory of Carcinogenesis, Cancer Research Institute, School of Basic Medical Science, Central South University, Changsha, China.
Jiawei ChenDepartment of Oncology, the Third Xiangya Hospital, Central South University, Changsha, China.
Yanfeng ZouDepartment of Oncology, the Third Xiangya Hospital, Central South University, Changsha, China.
Xuan WangDepartment of Oncology, the Third Xiangya Hospital, Central South University, Changsha, China.
Zhigang XiaoDepartment of General Surgery, The First Affiliated Hospital of Hunan Normal University (Hunan Provincial People's Hospital), Changsha, China.
Peiguo CaoDepartment of Oncology, the Third Xiangya Hospital, Central South University, Changsha, China. xy3caopg@csu.edu.cn.
Zheng LiNHC Key Laboratory of Carcinogenesis, Cancer Research Institute, School of Basic Medical Science, Central South University, Changsha, China. lizheng@csu.edu.cn.ORCID http://orcid.org/0000-0002-3758-8165

Funding

National Natural Science Foundation of China (National Science Foundation of China) 81872473
6 · The paper itself

Abstract

Colorectal cancer (CRC) progression is associated with intestinal barrier dysfunction, yet the molecular mechanisms governing mucin glycosylation remain unclear. This study aims to investigate the regulatory pathway controlling MUC2 expression and O-glycosylation in CRC and assess the therapeutic potential of rosiglitazone in restoring mucosal integrity. In this study, B3GNT6 was identified as a key glycosyltransferase that promotes MUC2 O-glycosylation and protein stability. KLF4 was shown to transcriptionally regulate both B3GNT6 and MUC2, with its activity modulated by PPARg. Treatment with the PPARg agonist rosiglitazone activated the PPARg-KLF4-B3GNT6 axis, restoring MUC2 function and enhancing the mucus barrier integrity. These findings highlight a novel therapeutic avenue for CRC by targeting mucin glycosylation.

Indexed as

Colorectal NeoplasmsMucin-2AnimalsCell Line, TumorDisease ProgressionGene Expression Regulation, NeoplasticGlycosylationHumansKruppel-Like Factor 4N-AcetylglucosaminyltransferasesPPAR gammaPPAR-gamma AgonistsRosiglitazoneKLF4 protein, humanKlf4 protein, mouseKruppel-Like Factor 4MUC2 protein, humanMucin-2N-AcetylglucosaminyltransferasesPPAR gammaPPAR-gamma AgonistsRosiglitazone

Identifiers

PMID42323288
PMCPMC13530250

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.